What is the appropriate starting dose of insulin Mixtard 70/30 (premixed human insulin containing 70% NPH and 30% regular insulin) for a 74‑kg male, and what definitive test should be used to determine whether his diabetes is type 1 or type 2?

Insulin Mixtard 70/30 Dosing and Diabetes Type Differentiation

Starting Dose for 74kg Male

For a 74kg male starting Mixtard 70/30 (premixed insulin), begin with approximately 15-22 units divided as 2/3 (10-15 units) before breakfast and 1/3 (5-7 units) before dinner, which translates to roughly 0.2-0.3 units/kg/day total. 1

Dosing Algorithm:

• Initial total daily dose: 0.2-0.3 units/kg/day = 15-22 units for 74kg patient
• Distribution: 2/3 before breakfast, 1/3 before dinner 1
  • Morning dose: 10-15 units
  • Evening dose: 5-7 units

Adjust the starting dose downward (toward 0.2 units/kg) if the patient has:

• Renal or hepatic impairment
• Normal or thin body habitus
• Elderly or frail status
• Risk factors for hypoglycemia 1

Adjust the starting dose upward (toward 0.3 units/kg or higher) if the patient has:

• Marked obesity with metabolic syndrome
• Active infections or open wounds
• Very high presenting glucose (≥300 mg/dL) or A1C (≥10%) 1

Titration Strategy:

Increase each component by 1-2 units or 10-15% every 3 days based on:

• Fasting glucose for morning dose adjustments
• Pre-dinner glucose for evening dose adjustments
• Target fasting plasma glucose per individualized goals 1

---

Definitive Test to Distinguish Type 1 vs Type 2 Diabetes

The most definitive test to differentiate type 1 from type 2 diabetes is measurement of diabetes-associated autoantibodies, specifically GAD65 antibodies, IA-2 antibodies, insulin autoantibodies (if not yet on insulin), and ZnT8 antibodies—positive results indicate type 1 diabetes (including latent autoimmune diabetes in adults). 2

Clinical Classification Approach:

Key clinical features suggesting Type 1:

• Younger age at onset (though can occur at any age)
• Acute presentation with polyuria/polydipsia
• Diabetic ketoacidosis at presentation (occurs in ~50% of children with type 1) 2
• Lean body habitus
• Absolute insulin requirement from diagnosis
• Family history of autoimmune disease

Key clinical features suggesting Type 2:

• Older age at onset (though can occur at any age)
• Gradual onset
• Obesity or metabolic syndrome features
• Acanthosis nigricans
• Strong family history of type 2 diabetes
• Initial response to oral agents 2

Laboratory Testing Panel:

1. Autoantibody panel (definitive):

   • GAD65 antibodies
   • IA-2 (insulinoma-associated-2) antibodies
   • Insulin autoantibodies (IAA) - only if not yet on insulin
   • ZnT8 antibodies

2. C-peptide level (supportive):

   • Low/absent C-peptide suggests type 1 (insulin deficiency)
   • Normal/elevated C-peptide suggests type 2 (insulin resistance)
   • Best measured fasting or stimulated (after mixed meal)

Important caveat: Some patients cannot be clearly classified at diagnosis, as type 1 diabetes in adults may progress more slowly (latent autoimmune diabetes in adults/LADA), and type 2 diabetes can eventually lead to significant beta-cell failure requiring insulin. 2 The presence of autoantibodies remains the gold standard for identifying autoimmune diabetes regardless of clinical presentation.

Why This Matters for Treatment:

The distinction is critical because:

• Type 1 patients require insulin from diagnosis and will never be successfully managed with oral agents alone
• Type 2 patients may initially respond to lifestyle modification and oral agents, though many eventually require insulin
• Misclassifying type 1 as type 2 and delaying insulin can lead to diabetic ketoacidosis and life-threatening complications 1, 2

When in doubt with high glucose (≥300 mg/dL) or A1C (≥10%), or any symptoms of hyperglycemia, start insulin immediately while awaiting autoantibody results rather than risk ketoacidosis. 1